Trending News
News
News
Gilead Acquires Nimbus Therapeutics’
Nimbus Therapeutics will receive an upfront payment of $400 million, with the potential to receive an additional $800 million in development-related milestones over time.
News
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
News
Fighting Early Stage Alzheimer's
Mouse study suggests possibility of curbing early synapse loss in Alzheimer’s.
News
Half a Million-Dollar Tick
How proteins present in tick saliva prevent the immune system from running amok.
News
Zika Virus Structure Revealed
Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.
News
Discovering 'Outlier' Enzymes
Researchers at TSRI and Salk Institute have discovered 'Outlier' enzymes that could offer new targets to treat type 2 diabetes and inflammatory disorders.
News
Thermo Acquires Affymetrix
Thermo Fisher Scientific and Affymetrix, has announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion.
News
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
News
qPAINT Counts Biomolecules Inside Cells
A new analytical tool endows DNA-powered super-resolution microscopy techniques with quantitative power.
News
New Targets for Diabetes, Inflammation Discovered
The Scripps Research Institute and Salk Scientists discover 'outlier' enzymes that could offer new targets to treat diabetes and inflammation.
Advertisement